Welcome to our dedicated page for Bellevue Life Sciences Acquisition news (Ticker: BLAC), a resource for investors and traders seeking the latest updates and insights on Bellevue Life Sciences Acquisition stock.
Bellevue Life Sciences Acquisition Corp. (BLAC) appears in news primarily in connection with its transformation into OSR Holdings, Inc. and the activities of the OSR healthcare group. News coverage traces the path from BLAC’s role as a special purpose acquisition company to the completion of its business combination with OSR Holdings Co., Ltd., after which the combined entity began trading on Nasdaq under the symbol OSRH.
Articles linked to the BLAC ticker describe key milestones such as the announcement and approval of the business combination, the related name change to OSR Holdings, Inc., and the expected commencement of trading under new ticker symbols. These reports outline how BLAC, as a SPAC, was formed to complete a merger or similar transaction and ultimately became the listed holding company for OSR’s healthcare businesses.
Subsequent news about OSR Holdings, Inc. provides additional context for readers following the BLAC history. Releases describe OSR Holdings’ portfolio of subsidiaries in immuno-oncology, regenerative biologics, and medical device distribution, as well as collaboration agreements such as a memorandum of understanding with SillaJen to share technology and clinical development resources in immuno-oncology.
More recent announcements highlight OSR Holdings, Inc.’s initiatives at the intersection of healthcare and blockchain, including an MOU to explore a security token provisionally named the OSRH Token and a roadmap for a Regulation D security token offering involving a token referred to as OSRT. These stories describe planned participation via Bitcoin (BTC), Tether (USDT), and Taekwondo Access Credit (TAC), and a broader strategy that combines crypto treasury concepts with healthcare innovation.
For users tracking BLAC-related news, this page therefore serves as an archive of the SPAC’s transition into OSR Holdings, Inc. and a gateway to ongoing coverage of OSR’s healthcare and digital asset activities under the successor ticker.
OSR Holdings (NASDAQ: OSRH) has unveiled plans for a $50 million security token offering (STO) under Regulation D in the second half of 2025. The company will launch OSRT, a security token representing equity exposure, accepting Bitcoin (BTC), Tether (USDT), and Taekwondo Access Credit (TAC) as subscription currencies.
The strategic roadmap includes restrictions on BCM Europe AG, OSR's largest shareholder, from directly using TAC for subscription. The company aims to build a $100 million Bitcoin and USDT reserve, supported by both the STO and an $80 million equity line of credit (ELOC) from White Lion GBM Innovation Fund. This initiative aligns with OSR's blockchain-based capital strategy and its focus on integrating decentralized finance with healthcare innovation.
OSR Holdings (NASDAQ: OSRH) has signed a Memorandum of Understanding (MOU) with BCM Europe AG and Taekwondo Cooperative (TKD Coop) to develop a security token called the "OSRH Token". The token will accept Bitcoin (BTC), Tether (USDT), and Taekwondo Access Credit (TAC) as subscription currencies.
The initiative aims to enhance crypto-based liquidity access and launch crypto treasury strategies. BCM Europe AG, OSRH's largest shareholder, intends to contribute its TAC token rights, reserve, and infrastructure to OSRH. TKD Coop, which has been using the TAC token since 2021, will continue leading blockchain adoption in the Taekwondo community. The MOU has a three-month term for finalizing the legal and technical framework.
OSR Holdings, Inc. (formerly Bellevue Life Sciences Acquisition Corp.) and OSR Holdings Co., have successfully completed their business combination. Following this merger, the company will operate under the name OSR Holdings, Inc. Starting Tuesday, February 18, 2025, the company's common stock and warrants will begin trading on the Nasdaq Stock Market under the new ticker symbols 'OSRH' and 'OSRHW' respectively.
Bellevue Life Sciences Acquisition Corp. (BLAC) has received stockholder approval for its business combination with OSR Holdings Co., The transaction is expected to close on February 14, 2025, following foreign investment approval from the Industrial Bank of Korea. The company has changed its name to OSR Holdings, Inc. and will trade on Nasdaq under symbols 'OSRH' and 'OSRHW' starting February 18, 2025.
Post-transaction, OSR Holdings will own approximately 67% of OSR Holdings Co., , with agreements in place to acquire an additional 22% of shares through put/call provisions beginning in 2026. The company's portfolio includes a Phase 2 clinical stage company developing immunotherapies for oncology, an early clinical stage company focusing on degenerative diseases, and a medical device distributions company operating across the US, Europe, and South Korea.
Bellevue Life Sciences Acquisitions Corp. (BLAC) has announced a Special Meeting to vote on extending the deadline for a business combination with OSR Holdings Co., , a healthcare holding company based in South Korea. Stockholders are encouraged to vote in favor of the Extension Amendment Proposal to extend the deadline from May 14, 2024, to November 14, 2024. Failure to secure at least 65% of votes may lead to liquidation and missed opportunities for stockholders.
Summary not available.
Summary not available.
Summary not available.
Summary not available.